Dr. Mark E. Wilson, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 407
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MS license 15570 -
Internal Medicine Physician
MS license 15570
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Billings Clinic Hospital Billings, MT
- Mississippi Baptist Medical Center Jackson, MS
- St Dominic-Jackson Memorial Hospital Jackson, MS
- Merit Health River Oaks Flowood, MS
- Copiah County Medical Center Hazlehurst, MS
Medical groups
- Billings Clinic Specialty Supplies and Services, LLC (824 clinicians)
- St. Dominic Medical Associates LLC (132 clinicians)
- Gastrointestinal Associates PA (46 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 407
- Services billed
- 5,668
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 5,400 | 13 |
| Injection, infliximab, excludes biosimilar, 10 mg | 1,667 | 17 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,006 | 99 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 562 | 99 |
| Biopsy of large bowel using a flexible endoscope | 188 | 186 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 120 | 117 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 107 | 26 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 97 | 26 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 90 | 89 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 59 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Jackson, MS | 225 |
| Omeprazole Other prescribers in Jackson, MS | 218 |
| Pantoprazole Sodium Other prescribers in Jackson, MS | 183 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 131 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Jackson, MS | 89 |
| Famotidine Other prescribers in Jackson, MS | 87 |
| Linzess (linaclotide) Other prescribers in Jackson, MS | 78 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 68 |
| Ondansetron Odt (ondansetron) Other prescribers in Jackson, MS | 32 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Jackson, MS | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 19 payments worth $524 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $168 |
|---|---|
| AbbVie Inc. | $73.37 |
| Takeda Pharmaceuticals U.S.A., Inc. | $71.89 |
| Regeneron Healthcare Solutions, Inc. | $61.58 |
| Ipsen Biopharmaceuticals, Inc | $53.92 |
| Janssen Biotech, Inc. | $24.69 |
| Qol Medical, LLC | $23.49 |
| Novo Nordisk Inc | $16.60 |
| Food and Beverage | $524 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $146,001 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.